Centre for Inflammation Research, Institute for Repair and Regeneration, University of Edinburgh, Edinburgh EH16 4UU, UK; Department of Critical Care, Intensive Care Unit, Queen Elizabeth University Hospital, Glasgow, UK.
Centre for Inflammation Research, Institute for Repair and Regeneration, University of Edinburgh, Edinburgh EH16 4UU, UK; Department of Critical Care, Royal Infirmary of Edinburgh, Edinburgh, UK.
Clin Chest Med. 2024 Dec;45(4):885-894. doi: 10.1016/j.ccm.2024.08.011. Epub 2024 Sep 10.
Acute respiratory distress syndrome (ARDS) is characterized by a dysregulated immune response to infection or injury. This framework has driven long-standing interest in immunomodulatory therapies as treatments for ARDS. In this narrative review, we first define what constitutes a dysregulated immune response in ARDS. In this context, we describe the rationale and available evidence for immunomodulatory therapies studied in randomized controlled trials of ARDS patients to date. Finally, we address factors that have contributed to the failure to develop therapies in the past and highlight current and future developments designed to address them.
急性呼吸窘迫综合征（ARDS）的特征是对感染或损伤的免疫反应失调。这一框架一直推动着人们对免疫调节疗法作为 ARDS 治疗方法的兴趣。在这篇叙述性综述中，我们首先定义了什么构成了 ARDS 中的免疫反应失调。在这方面，我们描述了迄今为止在 ARDS 患者随机对照试验中研究的免疫调节疗法的原理和现有证据。最后，我们讨论了过去导致疗法开发失败的因素，并强调了旨在解决这些问题的当前和未来的发展。
